Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas O Carpenter

Showing results (31-40 of 122) with videos related to

Pageof 13
Sort By:
BMC Pediatrics|January 18, 2012
Effects of ethnicity and vitamin D supplementation on vitamin D status and changes in bone mineral content in infantsSteven A Abrams, Keli M Hawthorne, Stefanie P Rogers, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 29, 2012
Heart failure in hypophosphatemic rickets: complications from high-dose phosphate therapyGrace E Ching Sun, Ozan Suer, Thomas O Carpenter, et al.
The New England Journal of Medicine|April 29, 2011
Calcitonin administration in X-linked hypophosphatemiaEva S Liu, Thomas O Carpenter, Caren M Gundberg, et al.
The Journal of Biological Chemistry|November 26, 2009
Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHOLiping Xiao, Takahiro Naganawa, Joseph Lorenzo, et al.
The Journal of Clinical Endocrinology and Metabolism|November 25, 2004
Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumorsThomas O Carpenter, Bruce K Ellis, Karl L Insogna, et al.
Journal of the Endocrine Society|October 20, 2023
Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked HypophosphatemiaChristine A Simpson, Anna Maria Santoro, Thomas O Carpenter, et al.
Journal of Clinical Pharmacology|August 7, 2015
Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemiaXiaoping Zhang, Thomas Peyret, Nathalie H Gosselin, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|June 10, 2021
Phosphorus bioaccessibility measured in four amino acid-based  formulas using in-vitro batch digestion translates well into phosphorus bioavailability in miceSampada Chande, Francina Dijk, Jonathan Fetene, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 4, 2011
A clinician's guide to X-linked hypophosphatemiaThomas O Carpenter, Erik A Imel, Ingrid A Holm, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 18, 2013
Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcificationSilje Hjorth Rafaelsen, Helge Raeder, Anne Kristine Fagerheim, et al.
Pageof 13

Showing results (31-40 of 122) with videos related to

Sort By:
Pageof 13
BMC Pediatrics|January 18, 2012
Effects of ethnicity and vitamin D supplementation on vitamin D status and changes in bone mineral content in infantsSteven A Abrams, Keli M Hawthorne, Stefanie P Rogers, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 29, 2012
Heart failure in hypophosphatemic rickets: complications from high-dose phosphate therapyGrace E Ching Sun, Ozan Suer, Thomas O Carpenter, et al.
The New England Journal of Medicine|April 29, 2011
Calcitonin administration in X-linked hypophosphatemiaEva S Liu, Thomas O Carpenter, Caren M Gundberg, et al.
The Journal of Biological Chemistry|November 26, 2009
Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHOLiping Xiao, Takahiro Naganawa, Joseph Lorenzo, et al.
The Journal of Clinical Endocrinology and Metabolism|November 25, 2004
Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumorsThomas O Carpenter, Bruce K Ellis, Karl L Insogna, et al.
Journal of the Endocrine Society|October 20, 2023
Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked HypophosphatemiaChristine A Simpson, Anna Maria Santoro, Thomas O Carpenter, et al.
Journal of Clinical Pharmacology|August 7, 2015
Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemiaXiaoping Zhang, Thomas Peyret, Nathalie H Gosselin, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|June 10, 2021
Phosphorus bioaccessibility measured in four amino acid-based  formulas using in-vitro batch digestion translates well into phosphorus bioavailability in miceSampada Chande, Francina Dijk, Jonathan Fetene, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 4, 2011
A clinician's guide to X-linked hypophosphatemiaThomas O Carpenter, Erik A Imel, Ingrid A Holm, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 18, 2013
Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcificationSilje Hjorth Rafaelsen, Helge Raeder, Anne Kristine Fagerheim, et al.
Pageof 13